Abstract: PO0015
Renal Comorbidities and New Acute Kidney Failure Drive Unfavorable Outcomes Among COVID-19-Positive Sickle Cell Trait Carriers
Session Information
- COVID-19: AKI and Basic Science
November 04, 2021 | Location: On-Demand, Virtual Only
Abstract Time: 10:00 AM - 12:00 PM
Category: Coronavirus (COVID-19)
- 000 Coronavirus (COVID-19)
Authors
- Iyengar, Sudha K., Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio, United States
- Minnier, Jessica, Biostatistics Shared Resource, Knight Cancer Institute, Oregon Health and Science University, Portland, Portland, Oregon, United States
- Verma, Anurag, Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
- Luoh, Shiuh-Wen, Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, United States
Group or Team Name
- Million Veteran Program COVID-19 Disease Mechanisms Working Group
Background
The sickle cell trait (SCT) in the hemoglobin beta gene (HbS; rs334) affects millions of Americans, especially African Americans (AA; minor allele frequency [MAF]=7.8%) and Hispanic Americans (HA; MAF=1%). We investigated the impact of SCT on the severity and sequelae of COVID-19 infection in the Million Veteran Program (MVP). Pre-COVID diseases and laboratory findings present in electronic health records (EHR), as well as acute events following 60 days of COVID-19 infection, and their effect on COVID-19 mortality among SCT patients were examined.
Methods
COVID-19 clinical data on genotyped MVP participants (SCT+ = 2,729, SCT-= 129,848; COVID+=13,841, COVID-=118,736) was extracted from EHR. Outcomes analyzed were: severe disease (or mortality) vs. not severe (or survival). Ethnic-specific firth logistic regression for SCT was performed on European (EA), African (AA), Hispanic (HA) and Asian (ASA) groups, adjusting for sex, age, age2, and 20 genetic principal components. Ethnic-specific phenome-wide association (PheWAS and LabWAS) for SCT captured 20+ years of comorbidities and historical laboratory values and was used to contrast effects of COVID-19. Multiple testing corrections were applied.
Results
HbS is associated with increased COVID-19 mortality in AA (N=3,749; OR=1.8 [1.14-2.84], p=0.01) with a similar trend in HA. PheWAS revealed significant associations of rs334 with phecodes for pulmonary embolism, chronic renal disease, diabetic kidney disease, hypertensive renal disease, gout, sickle cell disease/trait, and hemolytic anemia (FDR p < 0.1). After adjusting for SCT, past renal disease was significantly associated with higher COVID-19 deaths among AA. Increased incidence of acute kidney failure (AKF) and chronic kidney disease (CKD) were seen within 60 days of infection with COVID-19. We estimated direct and indirect effects of AKF or CKD in AA SCT carriers via a mediation framework. On average 20.7% (95% CI: 3.8% - 56.0%) of the total effect of SCT on COVID-19 death was found to be mediated through AKF, and that for CKD was 12.4% (95% CI: 0% - 63%).
Conclusion
SCT is associated with an elevated risk of mortality with COVID-19 infection. Both pre-existing chronic medical conditions and new acute events after COVID-19 may contribute to adverse COVID-19 outcomes with SCT.
Funding
- Veterans Affairs Support